Leerink assumed coverage of Mind Medicine with an Outperform rating and $20 price target The firm likes the emerging psychedelics space with increasing investment in clinical development across multiple psychiatric indications, clear FDA guidance, and more established commercial infrastructure following the launch of J&J’s Spravato. The firm also believes MM120 has a good chance of working based on published data.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on MNMD:

• Mind Medicine price target lowered to $14 from $16 at Canaccord

• MindMed Issues New Employee Share Options

• MindMed Showcases Innovation at Investor Events

• MindMed Reveals Breakthrough GAD Treatment Study

• Mind Medicine Highlights GAD’s Economic Impact